Log in with your email address username.


Attention doctorportal newsletter subscribers,

After December 2018, we will be moving elements from the doctorportal newsletter to MJA InSight newsletter and rebranding it to Insight+. If you’d like to continue to receive a newsletter covering the latest on research and perspectives in the medical industry, please subscribe to the Insight+ newsletter here.

As of January 2019, we will no longer be sending out the doctorportal email newsletter. The final issue of this newsletter will be distributed on 13 December 2018. Articles from this issue will be available to view online until 31 December 2018.

[Comment] Checkpoint inhibition: an ATTRACTION in advanced gastric cancer?

Annually, more than 950 000 people are diagnosed with gastric or oesophagogastric junction cancer1—the third most lethal cancer worldwide2—for which there is a considerable unmet clinical need. Blockade of immune checkpoints has been successfully integrated into standard treatment regimens for several solid tumours.3 The ATTRACTION-2 study by Yoon-Koo Kang and colleagues4 in The Lancet is, to my knowledge, the first randomised, placebo-controlled, phase 3 trial of immune checkpoint blockade in gastrointestinal cancers.